Prostate Cancer CTC PSMA Status Could Guide Therapy
PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
Diagnosis & Disease Information
Adding Ifosfamide to MAP Provides No Benefit in High-Grade Osteosarcoma
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
SBRT Does Not Improve Efficacy of Nivo-Ipi in Advanced Merkel Cell Carcinoma
SBRT did not improve the efficacy of nivolumab-ipilimumab in patients with advanced Merkel cell carcinoma in a phase 2 study.
Vaccine-Pembrolizumab Combo Appears Active in HPV+ Advanced Cervical Cancer
Combination treatment with the GX-188E vaccine and pembrolizumab can elicit responses in patients with HPV 16-/18-positive advanced cervical cancer.
Greater PSA Decline Predicts Better 177Lu-PSMA-617 Outcomes in mCRPC
PSA decline in men who receive 177Lu-PSMA-617 for mCRPC is associated with radiographic progression and death risk.
Real-World Data Support Nivolumab + Ipilimumab for First-Line mRCC Therapy
A real-world study revealed an objective response rate consistent with that observed in the CheckMate 214 trial.
Metronomic Chemotherapy Prolongs TTF, PFS in ER+/HER2- Metastatic Breast Cancer
An oral metronomic chemotherapy regimen appears more effective than paclitaxel for patients with ER+, HER2- metastatic breast cancer.
Liposomal Irinotecan Improves Upon 5-FU/LV in Refractory Pancreatic Cancer
Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.
Donafenib May Be Alternative for Progressive, Advanced RAIR-DTC
Donafenib demonstrated efficacy in patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective
Treatment with 177lutetium-PSMA-617 is safe and effective in patients with metastatic castration-resistant prostate cancer who have previously received 223radium.
- Loading...
Loading...
Next post in ESMO 2022
Loading... 
Loading...